氨基丹曲林 | 14663-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 氨基丹曲林
• 英文名称: Aminodantrolene
• 英文别名: 1-[(E)-[5-(4-aminophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
• CAS: 14663-28-6
• 化学式: C₁₄H₁₂N₄O₃
• 分子量: 284.27
• InChiKey: UXUTWFLSENWVIM-FRKPEAEDSA-N

物化性质

• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

文献信息

• Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
  申请人：US Worldmeds LLC

  公开号：EP2583670A1

  公开（公告）日：2013-04-24

  The present invention provides for methods of using terf-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

  本发明提供了在配制和生产低溶解度药剂时使用特氟醇（TBA）助溶剂体系的方法。本发明还提供了使用新型助溶剂体系制成的药物组合物。在一个实施方案中，本发明提供了一种用于静脉注射的丹曲林钠（DS）制剂（DS-IV）的制作方法。这种瞬时重组的 DS-IV 产品极大地改进了手术期间恶性高热病人的药物治疗。
• CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS
  申请人：US Worldmeds LLC

  公开号：EP2219605A1

  公开（公告）日：2010-08-25
• Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents
  申请人：Malkawi Ahmad

  公开号：US20090093531A1

  公开（公告）日：2009-04-09

  The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
• CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS
  申请人：Malkawi Ahmad

  公开号：US20110015243A2

  公开（公告）日：2011-01-20

  The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
• US8975284B2
  申请人：——

  公开号：US8975284B2

  公开（公告）日：2015-03-10